Drug General Information
Drug ID	D0XR7C
Former ID	DIB014060
Drug Name	YM-598
Indication	Prostate cancer [ICD9: 185; ICD10:C61]		Phase 2	[521539]
Company	Astellas
Structure		Download 2D MOL
Target and Pathway
Target(s)	Endothelin-1 receptor	Target Info	Antagonist	[544172]
KEGG Pathway	Calcium signaling pathway
	cGMP-PKG signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Vascular smooth muscle contraction
	Renin secretion
	Pathways in cancer
NetPath Pathway	IL4 Signaling Pathway
PANTHER Pathway	Endothelin signaling pathway
Pathway Interaction Database	Endothelins
	EGFR-dependent Endothelin signaling events
Reactome	Peptide ligand-binding receptors
	G alpha (q) signalling events
WikiPathways	Prostaglandin Synthesis and Regulation
	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Peptide GPCRs
	Endothelin Pathways
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 521539	ClinicalTrials.gov (NCT00050297) YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer. U.S. National Institutes of Health.
Ref 544172	Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol. 2011 May; 163(2): 220-233.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.